Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Colorcon
Deloitte
Boehringer Ingelheim
Baxter
Fish and Richardson

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,107,822

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,107,822
Title:Water-in oil type emulsion for treating a disease of the eye
Abstract: The invention relates to a composition for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. The invention also relates to a pharmaceutical composition or to a medicament comprising the composition of the invention, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of the composition of the invention. The invention also relates to a device comprising the composition of the invention.
Inventor(s): Lallemand; Frederic (Fresnes, FR), Garrigue; Jean-Sebastien (Verrieres-le-Buisson, FR), Philips; Betty (Antony, FR)
Assignee: SANTEN SAS (Evry, FR)
Application Number:13/820,456
Patent Claims:see list of patent claims

Details for Patent 9,107,822

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26 ➤ Sign Up SANTEN SAS (Evry, FR) 2030-09-03 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up SANTEN SAS (Evry, FR) 2030-09-03 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up SANTEN SAS (Evry, FR) 2030-09-03 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up SANTEN SAS (Evry, FR) 2030-09-03 RX search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30 ➤ Sign Up SANTEN SAS (Evry, FR) 2030-09-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Fish and Richardson
US Department of Justice
Moodys
Cantor Fitzgerald
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.